Skip to content
Clinical Trials – home
ItalyBack to Italy

Clinical trials in Pavia – page 136

2 866 clinical trials in Pavia, Italy across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Pavia at a glance
2 866
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

2 866 trials in Pavia

Open in trial search

Angelman's syndrome

Not recruiting

A Study Testing the Safety and How Well GTX-102 Works in Adults and Children with Angelman Syndrome

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Apazunersen
  • Sponsor:Ultragenyx Pharmaceutical Inc.

A Study of Mevrometostat and Enzalutamide for Men with Metastatic Castration-Sensitive Prostate Cancer Who Have Not Received Hormonal Therapy or Chemotherapy

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Pfizer Inc.

Study of ianalumab for adults with primary immune thrombocytopenia or warm-antibody autoimmune hemolytic anemia who previously responded to ianalumab

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Danazol
  • Sponsor:Novartis Pharma AG

Multiple sclerosis

Not recruiting

A Study Comparing Two Forms of Ocrelizumab Given Under the Skin in Patients with Multiple Sclerosis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:F. Hoffmann-La Roche AG

A study testing MK-1167 added to current treatment in patients with mild to moderate Alzheimer's disease dementia

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:MK-1167
  • Sponsor:Merck Sharp & Dohme LLC

Prostate cancer

Not recruiting

Study of xaluritamig compared to cabazitaxel or androgen receptor therapy for patients with metastatic castration-resistant prostate cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Amgen Inc.

A Study Comparing Telisotuzumab Adizutecan to Trifluridine, Tipiracil, and Bevacizumab in Adults with Refractory Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

A study comparing BNT113 combined with pembrolizumab versus pembrolizumab alone for patients with HPV16-positive head and neck cancer that cannot be removed by surgery

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:BioNTech SE

Ovarian cancer

Not recruiting

Study of tuvusertib combined with niraparib or lartesertib for patients with ovarian cancer that worsened after previous PARP inhibitor treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Lartesertib
  • Sponsor:Merck Healthcare KGaA

Chronic hepatitis B

Not recruiting

Study of GSK3965193 and Bepirovirsen for People Living with Chronic Hepatitis B Infection and Healthy Participants

Investigational
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Bepirovirsen
  • Sponsor:Glaxosmithkline Research & Development Limited

Migraine

Not recruiting

Study of Erenumab Compared to Placebo for Children and Adolescents with Episodic Migraine to Reduce Monthly Migraine Days

Investigational
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Erenumab
  • Sponsor:Amgen Inc.

Migraine

Not recruiting

A Study of Erenumab Compared to Placebo for Children and Teenagers With Chronic Migraine to Test How Well It Works and How Safe It Is

Investigational
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Erenumab
  • Sponsor:Amgen Inc.

Other cities in Italy

The busiest research cities in the country

All 232 cities in Italy

Clinical research in Pavia

What the registry says about research in the country

01 Cardiovascular Research

Groundbreaking studies focusing on heart failure prevention and innovative treatments for cardiac conditions, including research on TTR amyloidosis and specialized therapies for pulmonary hypertension.

  • Heart Disease Prevention
  • Pulmonary Arterial Hypertension
  • Ventricular Tachycardia

Clinical trials evaluating new therapeutic approaches for cardiovascular complications and heart rhythm disorders.

02 Neurological Disorders

Studies investigating treatments for acute ischemic stroke and progressive neurological conditions, with particular focus on improving patient outcomes and functional recovery.

  • Stroke Treatment
  • Parkinson's Disease
  • Dravet Syndrome

Advanced research exploring innovative therapeutic approaches for various neurological conditions.

03 Autoimmune and Inflammatory Conditions

Research targeting chronic spontaneous urticaria, various forms of arthritis, and systemic autoimmune conditions affecting multiple organ systems.

  • Psoriatic Arthritis
  • Systemic Sclerosis
  • Immune System Disorders

Evaluation of novel therapies aimed at managing inflammatory responses and improving quality of life.

04 Respiratory Medicine

Comprehensive studies on chronic obstructive pulmonary disease and bronchiectasis, focusing on exacerbation prevention and symptom management.

  • COPD Treatment
  • Non-Cystic Fibrosis Bronchiectasis
  • Lung Fibrosis

Investigation of innovative therapeutic approaches for chronic respiratory conditions.

05 Hematology and Oncology

Advanced research in multiple myeloma and related blood disorders, including chronic myeloid leukemia and myelodysplastic syndromes.

  • Blood Cancers
  • Amyloidosis
  • Transfusion-Dependent Anemia

Development of targeted therapies for various hematological conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.